CN113599422B - Composition with anti-sugar effect and application thereof - Google Patents
Composition with anti-sugar effect and application thereof Download PDFInfo
- Publication number
- CN113599422B CN113599422B CN202111041930.8A CN202111041930A CN113599422B CN 113599422 B CN113599422 B CN 113599422B CN 202111041930 A CN202111041930 A CN 202111041930A CN 113599422 B CN113599422 B CN 113599422B
- Authority
- CN
- China
- Prior art keywords
- parts
- powder
- roxburgh rose
- composition
- sugar
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 39
- 230000000694 effects Effects 0.000 title claims abstract description 20
- 241000220317 Rosa Species 0.000 claims abstract description 25
- 150000004676 glycans Chemical class 0.000 claims abstract description 22
- 229920001282 polysaccharide Polymers 0.000 claims abstract description 22
- 239000005017 polysaccharide Substances 0.000 claims abstract description 22
- 241000208340 Araliaceae Species 0.000 claims abstract description 19
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 19
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 19
- 235000008434 ginseng Nutrition 0.000 claims abstract description 19
- 150000008442 polyphenolic compounds Chemical class 0.000 claims abstract description 18
- 235000013824 polyphenols Nutrition 0.000 claims abstract description 18
- 239000003814 drug Substances 0.000 claims abstract description 14
- 239000002994 raw material Substances 0.000 claims abstract description 14
- 235000013406 prebiotics Nutrition 0.000 claims abstract description 12
- 235000003417 Plumeria rubra f acutifolia Nutrition 0.000 claims abstract description 11
- 244000040691 Plumeria rubra f. acutifolia Species 0.000 claims abstract description 11
- 206010012601 diabetes mellitus Diseases 0.000 claims abstract description 6
- 244000269722 Thea sinensis Species 0.000 claims abstract 6
- 239000000843 powder Substances 0.000 claims description 31
- 241000628997 Flos Species 0.000 claims description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- 235000011389 fruit/vegetable juice Nutrition 0.000 claims description 6
- 229940089161 ginsenoside Drugs 0.000 claims description 5
- 229930182494 ginsenoside Natural products 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 4
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 claims description 3
- HEBKCHPVOIAQTA-NGQZWQHPSA-N d-xylitol Chemical compound OC[C@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-NGQZWQHPSA-N 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 3
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 claims description 3
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 claims description 3
- 229940107187 fructooligosaccharide Drugs 0.000 claims description 3
- 235000021255 galacto-oligosaccharides Nutrition 0.000 claims description 3
- 150000003271 galactooligosaccharides Chemical class 0.000 claims description 3
- 238000001556 precipitation Methods 0.000 claims description 3
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 claims description 3
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 claims description 3
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 claims description 3
- 235000005493 rutin Nutrition 0.000 claims description 3
- 229960004555 rutoside Drugs 0.000 claims description 3
- 238000000926 separation method Methods 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
- 230000005764 inhibitory process Effects 0.000 abstract description 11
- 239000001301 oxygen Substances 0.000 abstract description 11
- 229910052760 oxygen Inorganic materials 0.000 abstract description 11
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract description 8
- 230000015572 biosynthetic process Effects 0.000 abstract description 7
- 235000013305 food Nutrition 0.000 abstract description 6
- 201000010099 disease Diseases 0.000 abstract description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 5
- 229940079593 drug Drugs 0.000 abstract description 5
- 230000007760 free radical scavenging Effects 0.000 abstract description 4
- 230000036541 health Effects 0.000 abstract description 4
- 230000003712 anti-aging effect Effects 0.000 abstract 1
- 230000003064 anti-oxidating effect Effects 0.000 abstract 1
- AIJULSRZWUXGPQ-UHFFFAOYSA-N Methylglyoxal Chemical compound CC(=O)C=O AIJULSRZWUXGPQ-UHFFFAOYSA-N 0.000 description 30
- 241001122767 Theaceae Species 0.000 description 19
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 12
- 241000699670 Mus sp. Species 0.000 description 11
- 210000004369 blood Anatomy 0.000 description 10
- 239000008280 blood Substances 0.000 description 10
- 235000021070 high sugar diet Nutrition 0.000 description 10
- 210000002966 serum Anatomy 0.000 description 9
- 150000001875 compounds Chemical class 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- GLEVLJDDWXEYCO-UHFFFAOYSA-N Trolox Chemical compound O1C(C)(C(O)=O)CCC2=C1C(C)=C(C)C(O)=C2C GLEVLJDDWXEYCO-UHFFFAOYSA-N 0.000 description 7
- 150000003254 radicals Chemical class 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 102000004877 Insulin Human genes 0.000 description 6
- 108090001061 Insulin Proteins 0.000 description 6
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 6
- 102000019197 Superoxide Dismutase Human genes 0.000 description 6
- 108010012715 Superoxide dismutase Proteins 0.000 description 6
- 239000003963 antioxidant agent Substances 0.000 description 6
- 230000003078 antioxidant effect Effects 0.000 description 6
- 235000006708 antioxidants Nutrition 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 108700004049 glycosylated serum Proteins 0.000 description 6
- 229940125396 insulin Drugs 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- UBDZFAGVPPMTIT-UHFFFAOYSA-N 2-aminoguanidine;hydron;chloride Chemical compound [Cl-].NC(N)=N[NH3+] UBDZFAGVPPMTIT-UHFFFAOYSA-N 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- 108010014663 Glycated Hemoglobin A Proteins 0.000 description 5
- 102000017011 Glycated Hemoglobin A Human genes 0.000 description 5
- 239000008103 glucose Substances 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 108010005094 Advanced Glycation End Products Proteins 0.000 description 4
- 102000004506 Blood Proteins Human genes 0.000 description 4
- 108010017384 Blood Proteins Proteins 0.000 description 4
- 238000009825 accumulation Methods 0.000 description 4
- 238000006206 glycosylation reaction Methods 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 229940118019 malondialdehyde Drugs 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 230000036542 oxidative stress Effects 0.000 description 4
- -1 oxygen free radical Chemical class 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000001514 detection method Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 230000013595 glycosylation Effects 0.000 description 3
- 201000001421 hyperglycemia Diseases 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000002000 scavenging effect Effects 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- LXEKPEMOWBOYRF-QDBORUFSSA-N AAPH Chemical compound Cl.Cl.NC(=N)C(C)(C)\N=N\C(C)(C)C(N)=N LXEKPEMOWBOYRF-QDBORUFSSA-N 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- 102000004895 Lipoproteins Human genes 0.000 description 2
- 108090001030 Lipoproteins Proteins 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 230000002292 Radical scavenging effect Effects 0.000 description 2
- 240000002547 Rosa roxburghii Species 0.000 description 2
- 235000000640 Rosa roxburghii Nutrition 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- HAMNKKUPIHEESI-UHFFFAOYSA-N aminoguanidine Chemical compound NNC(N)=N HAMNKKUPIHEESI-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000001784 detoxification Methods 0.000 description 2
- NJDNXYGOVLYJHP-UHFFFAOYSA-L disodium;2-(3-oxido-6-oxoxanthen-9-yl)benzoate Chemical compound [Na+].[Na+].[O-]C(=O)C1=CC=CC=C1C1=C2C=CC(=O)C=C2OC2=CC([O-])=CC=C21 NJDNXYGOVLYJHP-UHFFFAOYSA-L 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 235000020710 ginseng extract Nutrition 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000002427 irreversible effect Effects 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 2
- 229960003105 metformin Drugs 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 239000002516 radical scavenger Substances 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- CCTFAOUOYLVUFG-UHFFFAOYSA-N 2-(1-amino-1-imino-2-methylpropan-2-yl)azo-2-methylpropanimidamide Chemical compound NC(=N)C(C)(C)N=NC(C)(C)C(N)=N CCTFAOUOYLVUFG-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 229930182843 D-Lactic acid Natural products 0.000 description 1
- JVTAAEKCZFNVCJ-UWTATZPHSA-N D-lactic acid Chemical compound C[C@@H](O)C(O)=O JVTAAEKCZFNVCJ-UWTATZPHSA-N 0.000 description 1
- 208000002249 Diabetes Complications Diseases 0.000 description 1
- 206010012655 Diabetic complications Diseases 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- GZCGUPFRVQAUEE-SLPGGIOYSA-N aldehydo-D-glucose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O GZCGUPFRVQAUEE-SLPGGIOYSA-N 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 230000006851 antioxidant defense Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 208000013677 cerebrovascular dementia Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 229940022769 d- lactic acid Drugs 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 238000012921 fluorescence analysis Methods 0.000 description 1
- 238000002795 fluorescence method Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 231100000025 genetic toxicology Toxicity 0.000 description 1
- 230000001738 genotoxic effect Effects 0.000 description 1
- OAKJQQAXSVQMHS-UHFFFAOYSA-N hydrazine Substances NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 125000000468 ketone group Chemical group 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 230000000269 nucleophilic effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 230000003820 β-cell dysfunction Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/489—Sophora, e.g. necklacepod or mamani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/738—Rosa (rose)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Nutrition Science (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The application discloses a composition with an anti-sugar effect, which comprises the following raw materials in parts by weight: 1-50 parts of apple polyphenol, 1-50 parts of pagodatree flower bud, 1-50 parts of tea polysaccharide, 0.5-30 parts of roxburgh rose, 1-50 parts of ginseng and 0.1-30 parts of prebiotics; the composition has obvious AGEs formation inhibition effect and extremely strong oxygen free radical scavenging capability, has wide application prospect in the fields of antioxidation, anti-aging and anti-diabetes in the future, and can be used for preparing medicines, foods and health care products for treating, delaying or improving AGEs related diseases.
Description
Technical Field
The application relates to the fields of medicines, health-care products and foods, in particular to a composition with an anti-sugar effect and application thereof.
Background
Glucose and fructose metabolism produce Methylglyoxal (MG), a highly reactive byproduct, which can react with free amino groups in macromolecules such as proteins to produce reversible or irreversible conjugates, i.e., advanced glycation end products (advanced glycosylation end products, AGEs). MG exists in various tissues, organs and blood in the human body, and can enter the human body through an external source (such as high MG food), and can also be generated by in vivo metabolic disorders (such as diabetes). Studies have shown that: 1) MG can react with circulating proteins and lipoproteins, resulting in protein dysfunction, e.g., glycosylated hemoglobin, modified lipoproteins causing dyslipidaemia and atherosclerosis; 2) Accumulation of MG in the extracellular matrix may lead to modification of collagen and other structural proteins, thickening and fibrosis of the extracellular matrix, such as skin aging, loss of elasticity of the vessel wall; 3) In cells, MG induces oxidative stress, accumulation of misfolded proteins, endoplasmic reticulum stress, genotoxicity (chemical modification of DNA), etc., and may damage the body's detoxification system, causing cell damage in humans. For example, MG causes insulin resistance and beta cell dysfunction, are early factors in the development of type ii diabetes, and form a vicious circle between glycosylation and hyperglycemia. 4) In addition, MG is also an effective oxidative stress inducer. Both oxidative stress and MG levels are increased in diabetics, while the antioxidant defenses are significantly reduced, which results in increased glycosylation and the formation of a malignant cycle of ROS/AGE.
In conclusion, MG is extremely easy to react with in-vivo proteins to produce AGEs, causes various cell dysfunction and oxidative stress increase of human bodies, and is one of main causes of diabetic complications such as retinopathy, nephropathy and neuropathy; but also in the occurrence of cardiovascular diseases and central nervous system diseases such as cerebrovascular diseases and dementia.
Currently, viable strategies to reduce AGEs accumulation and toxicity include: 1) Regulating endogenous enzyme GLO system (GLO 1 catalyzes MG reaction to D-lactic acid), increasing human body detoxification function, and reducing AGEs generation; 2) Inhibiting the generation of AGEs induced by MG; 3) Increasing the scavenging of oxygen free radical ROS, breaking the self-vicious cycle of ROS/AGE.
Although many synthetic and natural components have been shown to inhibit AGEs, there is still a long way to follow from an effective treatment regimen. Among them, aminoguanidine is one of the most studied AGEs inhibitors at present. The micromolecular nucleophilic hydrazine compound has oxidation resistance, can eliminate hydroxyl free radicals and cut off the crosslinking of AGEs, can reduce the content of cholesterol and triacylglycerol and reduce the accumulation of exogenous AGEs in the body, but aminoguanidine and the compound thereof have adverse reactions found in clinical experiments and cannot be applied in clinical practice, so the stage of clinical research is exited. Therefore, development of novel AGEs inhibitors without adverse reactions is urgent.
Disclosure of Invention
The application provides a composition with an anti-sugar effect and application thereof.
The application provides a composition with an anti-sugar effect, which comprises the following raw materials in parts by weight: 1-50 parts of apple polyphenol, 1-50 parts of pagodatree flower bud, 1-50 parts of tea polysaccharide, 0.5-30 parts of roxburgh rose, 1-50 parts of ginseng and 0.1-30 parts of prebiotics.
Preferably, the raw materials comprise, by weight, 5-25 parts of apple polyphenol, 10-40 parts of pagodatree flower bud, 1-20 parts of tea polysaccharide, 1-10 parts of roxburgh rose, 1-5 parts of ginseng and 10-30 parts of prebiotics.
Preferably, the raw materials comprise, by weight, 15 parts of apple polyphenol, 35 parts of pagodatree flower bud, 15 parts of tea polysaccharide, 5 parts of roxburgh rose, 5 parts of ginseng and 25 parts of prebiotics.
Preferably, the tea polysaccharide is tea polysaccharide powder with content of 10-40%.
Preferably, the tea polysaccharide is prepared by extracting subtropical old tea with weak alkaline water, adding ethanol for precipitation and separation, and finally drying to obtain tea polysaccharide powder with the content of 10-40%.
Preferably, the apple polyphenol is apple polyphenol powder with the content of 20% -30%.
Preferably, the flos Sophorae Immaturus is flos Sophorae Immaturus extract or flos Sophorae Immaturus powder or flos Sophorae Immaturus instant powder with rutin content of 10-20%.
Preferably, the ginseng is ginseng powder or ginseng extract with 45-50% of ginsenoside content.
Preferably, the roxburgh rose is roxburgh rose powder or roxburgh rose extract or roxburgh rose juice freeze-dried powder or roxburgh rose juice; the prebiotics are selected from one or more of fructo-oligosaccharide, xylo-oligosaccharide and galacto-oligosaccharide.
Also provides the application of the composition with the anti-sugar effect in preparing medicines or foods for treating, delaying or relieving AGEs related diseases and health care products.
The application has the beneficial effects that:
1. the sugar-resistant composition has obvious AGEs formation-resistant activity and oxygen free radical scavenging activity and dose dependence through analysis of AGEs generation-resistant and oxygen free radical scavenging abilities;
2. the anti-sugar composition can obviously reduce the index of hyperglycemia such as fasting blood glucose, glycosylated hemoglobin, glycosylated serum protein, serum insulin, serum malondialdehyde and the like of a high-sugar diet mouse, and can obviously raise the level of superoxide dismutase in the serum of the high-sugar diet mouse. In conclusion, the anti-sugar composition can remarkably improve endogenous antioxidant capacity of the high-sugar diet mice, reduce the occurrence of saccharification of serum proteins and plasma proteins of the high-sugar diet mice, and reduce the blood sugar level of the high-sugar diet mice, so that the effects of improving and treating diabetes are achieved.
Drawings
FIG. 1 is a Trolox standard curve.
Detailed Description
The application is further described in connection with the following detailed description, in order to make the technical means, the creation characteristics, the achievement of the purpose and the effect of the application easy to understand.
The application provides the following technical scheme:
the composition with the anti-sugar effect comprises auxiliary materials, and the following components in parts by weight: 1-50 parts of apple polyphenol, 1-50 parts of pagodatree flower bud, 1-50 parts of tea polysaccharide, 0.5-30 parts of roxburgh rose, 1-50 parts of ginseng and 0.1-30 parts of prebiotics.
Preferably, the raw materials comprise, by weight, 5-25 parts of apple polyphenol, 10-40 parts of pagodatree flower bud, 1-20 parts of tea polysaccharide, 1-10 parts of roxburgh rose, 1-5 parts of ginseng and 10-30 parts of prebiotics.
Preferably, the raw materials comprise, by weight, 15 parts of apple polyphenol, 35 parts of pagodatree flower bud, 15 parts of tea polysaccharide, 5 parts of roxburgh rose, 5 parts of ginseng and 25 parts of prebiotics.
Preferably, the tea polysaccharide is specifically tea polysaccharide powder with the content of 10-40%.
Preferably, the tea polysaccharide is prepared by extracting subtropical old tea with weak alkaline water, adding ethanol for precipitation and separation, and finally drying to obtain tea polysaccharide powder with the content of 10-40%.
Preferably, the apple polyphenol is specifically apple polyphenol powder with the content of 20-30%.
Preferably, the flos Sophorae Immaturus is flos Sophorae Immaturus extract or flos Sophorae Immaturus powder or flos Sophorae Immaturus instant powder with rutin content of 10-20%.
Preferably, the ginseng is specifically ginseng powder or ginseng extract with 45-50% of ginsenoside content.
Preferably, the roxburgh rose is specifically roxburgh rose powder or roxburgh rose extract or roxburgh rose juice freeze-dried powder or roxburgh rose juice; the prebiotics are selected from one or more of fructo-oligosaccharide, xylo-oligosaccharide and galacto-oligosaccharide.
Preferably, the auxiliary material is selected from one or more of sweetener, sour agent, filler, lubricant, suspension, binder, excipient or preservative.
Also provides the application of the composition with the anti-sugar effect in preparing medicines or foods for treating, delaying or relieving AGEs related diseases and health care products.
Test example 1: AGE production inhibitor and oxygen radical ROS scavenger screening
1) AGE production inhibitor screening
Principle of: the non-enzymatic glycosylation reaction in living body refers to the process that aldehyde or ketone groups of reducing sugar react with free amino groups in macromolecules such as proteins to generate reversible or irreversible conjugate, namely advanced glycosylation end products (advanced glycation end products, AGEs) under the condition of no enzymatic catalysis. The protein glycosylation reaction model of bovine serum albumin-methylglyoxal (bovine serum albumin methylglyoxal, BSA-MGO) is adopted, the content of AGEs is measured by a fluorescence method, and the inhibition effect of each compound on the formation of AGEs is studied.
Test compound: apple polyphenol (20-30%), pagodatree flower bud powder (10-20%), tea polysaccharide (10-40%), rosa roxburghii powder and ginseng powder (45-50%) of ginsenoside.
Auxiliary materials: BSA (bi cloud), methylglyoxal MGO (sigma), aminoguanidine hydrochloride (MCE), 96-well clear master (Nunc).
The method comprises the following steps: the compound or aminoguanidine hydrochloride is dissolved in PBS, the concentration is 1mg/mL and 200 mu g/mL, 50 mu L of aminoguanidine hydrochloride (300 mu M) of positive medicine is respectively placed in a 96-well plate, 50 mu L of BSA solution and 10mg/mL of BSA solution are added, 250mM of MGO 50 mu L are sequentially added, incubation is carried out for 48 hours at 37 ℃, the mixture is placed in an enzyme-labeled instrument (lambda exc: 370 nm; lambda em: 440 nm) to detect fluorescence intensity, and the inhibition rate of AGEs formation of different compounds is calculated by substituting the following formula, and the result is shown in the table.
The calculation formula is as follows: AGEs inhibition (%) = (1-a sample/a blank) ×100%.
2) Oxygen radical scavenger screening
Principle of: the ability to scavenge oxidative free radicals is also known as antioxidant. The ORAC analysis method is based on the principle that the free radical breaks down the fluorescent probe to change the fluorescence intensity, and uses FLIPR to conduct real-time fluorescence analysis by taking the vitamin E water-soluble analogue Trolox as a quantitative standard. The magnitude of the change in fluorescence intensity reflects the degree of free radical destruction. In the presence of an antioxidant, it can inhibit the change in fluorescence caused by free radicals. The extent of inhibition reflects its antioxidant capacity towards free radicals.
Test compound: apple polyphenol (20-30%), pagodatree flower bud powder (10-20%), tea polysaccharide (10-40%), rosa roxburghii powder and ginseng powder (45-50%) of ginsenoside.
Auxiliary materials: a 96-well black transparent bottom plate is purchased from Nunc company; sodium fluorescein was purchased from Shanghai Source leaf company; AAPH (2, 2' -azobis (2-amidinopropane) dihydrochloride) available from apebrio corporation; PBS (phosphate buffer pH 7.4) was purchased from Gbico company; the detection platform is FLIPR-TETRA, the detected signal is relative fluorescence intensity (RFU), and the area under the fluorescence curve (AUC) is detected by utilizing the Screen works ™ system software in the detection platform.
The method comprises the following steps: the composition or Trolox was dissolved in PBS to prepare 1mg/mL and 200. Mu.g/mL concentrations, 50. Mu.L of each concentration was placed in a 96-well plate, and 100. Mu.L of 100nM sodium fluorescein was added. Incubation was carried out at 37℃for 10min, 100mM AAPH 50. Mu.L was added, and the fluorescence intensity was measured every 30s for a total of 1h. The area under the fluorescence curve AUC, net area = AUC sample-AUC phosphate buffer, and the antioxidant concentration, test agent concentration-net area standard curve was calculated. The Trolox standard curve is shown in fig. 1, and R2 is 0.9557. ORAC values were measured for the different compounds, respectively, and the results are shown in Table one.
3) Experimental results
Table 5 evaluation results of AGEs production inhibition and oxygen radical scavenging ability
Remarks: trolox standard curve as shown in FIG. 1
ORAC values are compared with reference to Trolox standard curve, and AGEs (R) inhibition rate is compared with reference to AGEs (R) inhibition rate of aminoguanidine hydrochloride, so that the results show that the above 5 samples can inhibit AGEs from generating and scavenging oxygen free radicals, and can be used for preventing or improving AGEs related diseases such as diabetes syndrome, atherosclerosis and the like. The medicine, food or health care product formed by the combination of the compounds can provide a new thought and approach for preventing the occurrence and development of AGEs related diseases.
Example 1
The composition related to the embodiment is prepared from the following raw materials in parts by weight:
the preparation method comprises the following steps: weighing and mixing the raw materials.
Example 2:
the composition related to the embodiment is prepared from the following raw materials in parts by weight:
the preparation method comprises the following steps: weighing and mixing the raw materials.
Example 3:
the composition related to the embodiment is prepared from the following raw materials in parts by weight:
the preparation method comprises the following steps: weighing and mixing the raw materials.
The AGEs inhibitory compositions obtained by mixing examples 1 to 3 were examined for their inhibitory effect on the formation of AGEs and their scavenging effect on oxygen radicals by referring to the method of test example 1.
The test results are as follows:
table two 3 results of evaluation of AGEs production inhibition and oxygen radical scavenging ability
ORAC values are compared with reference to Trolox standard curve, AGEs (R) inhibition rate is compared with reference to AGEs (R) inhibition rate of 1mg/ml aminoguanidine hydrochloride, and test results show that examples 1-3 have obvious AGEs formation resistance and oxygen free radical scavenging activity and have dose dependence.
Evaluation of antidiabetic efficacy of the anti-sugar composition on laboratory animals
Materials: example 2 composition (apple polyphenol 15 parts, locust flour 35 parts, tea polysaccharide 15 parts, roxburgh rose powder 5 parts, ginseng powder 5 parts, fructo-oligosaccharides 25 parts) db/db mice (Jizhikang), ELISA kit (Biyun days), metformin (Zhongshanghai Guibao pharmaceutical Co., ltd.).
The mice are adapted to the environment for 3 days, and fed with high-sugar high-fat mice after 3 days, the stomach-resistant composition (300 mg/kg at low dose and 500mg/kg at high dose) is infused regularly every day, the model control group is infused with normal saline, the positive drug group is metformin (300 mg/kg/d), and the continuous administration is carried out for 4 weeks. Whole blood is collected, and after standing, the whole blood is centrifuged, serum is separated, and blood glucose, glycosylated Serum Protein (GSP), glycosylated hemoglobin (HbA 1 c), INS (serum insulin), malondialdehyde content (MDA), superoxide dismutase activity (SOD) and the like in the blood are detected respectively by using a full-automatic biochemical analyzer and an ELISA method. The detection results are shown in tables three-eight, and the anti-sugar composition can obviously reduce the index of hyperglycemia such as fasting blood glucose, glycosylated hemoglobin, glycosylated serum protein, serum insulin, serum malondialdehyde and the like of the high-sugar diet mice, and can obviously raise the level of superoxide dismutase in the serum of the high-sugar diet mice. In conclusion, the anti-sugar composition can remarkably improve endogenous antioxidant capacity of the high-sugar diet mice, reduce the occurrence of saccharification of serum proteins and plasma proteins of the high-sugar diet mice, and reduce the blood sugar level of the high-sugar diet mice, so that the effects of improving and treating diabetes are achieved.
Table three: change of glycosylated hemoglobin (HbA 1 c)
| Group of | Animal number (only) | HbA1c (%) was administered for 4 weeks |
| Model control group | 10 | 14.2±1.11 |
| Positive medicine group | 10 | 9.71±1.51** |
| High dose group of anti-sugar compositions | 10 | 9.03±1.14** |
| Low dose group of anti-sugar compositions | 10 | 9.82±1.02** |
Table four: changes in fasting blood glucose
| Group of | Animal number (only) | Before administration (mmol/L) | Administration was for 4 weeks (mmol/L) |
| Model control group | 10 | 16.55±7.19 | 15.29±4.90 |
| Positive medicine group | 10 | 16.35±6.85 | 6.77±1.60** |
| High dose group of anti-sugar compositions | 10 | 16.75±8.38 | 7.56±3.26** |
| Low dose group of anti-sugar compositions | 10 | 16.34±5.43 | 9.77±2.22* |
Table five: change of Glycosylated Serum Protein (GSP)
| Group of | Animal number (only) | Administration is carried out for 4 weeks (umol/L) |
| Model control group | 10 | 347.53±29.44 |
| Positive medicine group | 10 | 177.74±14.97** |
| High dose group of anti-sugar compositions | 10 | 201.60±46.53** |
| Low dose group of anti-sugar compositions | 10 | 251.00±13.61** |
Table six: serum Insulin (INS) change
| Group of | Animal number (only) | Administration is 4 weeks (mIU/L) |
| Model control group | 10 | 55.66±5.32 |
| Positive medicine group | 10 | 27.43±3.38** |
| High dose group of anti-sugar compositions | 10 | 27.31±1.99** |
| Low dose group of anti-sugar compositions | 10 | 36.86±3.66** |
Table seven: variation of superoxide dismutase (SOD) activity
| Group of | Animal number (only) | Administration is 4 weeks (U/mL) |
| Model control group | 10 | 161.73±22.22 |
| Positive medicine group | 10 | 301.64±33.01** |
| High dose group of anti-sugar compositions | 10 | 279.41±14.32** |
| Low dose group of anti-sugar compositions | 10 | 156.88±19.55* |
Table eight: malondialdehyde content (MDA) variation
| Group of | Animal number (only) | Administration was for 4 weeks (nmol/mL) |
| Model control group | 10 | 15.88±2.29 |
| Positive medicine group | 10 | 7.27±2.62** |
| High dose group of anti-sugar compositions | 10 | 8.05±2.35** |
| Low dose group of anti-sugar compositions | 10 | 13.23±2.28* |
The above examples merely illustrate specific embodiments of the application, which are described in more detail and are not to be construed as limiting the scope of the application. It should be noted that it is possible for a person skilled in the art to make several variants and modifications without departing from the technical idea of the application, which fall within the scope of protection of the application.
Claims (3)
1. The composition with the anti-sugar effect is characterized by comprising the following raw materials in parts by weight: 5-25 parts of apple polyphenol, 10-40 parts of pagodatree flower bud, 1-20 parts of tea polysaccharide, 1-10 parts of roxburgh rose, 1-5 parts of ginseng and 10-30 parts of prebiotics; the apple polyphenol is apple polyphenol powder with the content of 20-30%; the flos Sophorae Immaturus is flos Sophorae Immaturus extract or flos Sophorae Immaturus powder or flos Sophorae Immaturus instant powder with rutin content of 10-20%; the tea polysaccharide is prepared by extracting subtropical old tea with weak alkaline water, adding ethanol for precipitation separation, and finally drying to obtain tea polysaccharide powder with the content of 10-40%; the roxburgh rose is roxburgh rose powder or roxburgh rose extract or roxburgh rose juice freeze-dried powder or roxburgh rose juice; the Ginseng radix is Ginseng radix powder or Ginseng radix extract with ginsenoside content of 45-50%; the prebiotics are selected from one or more of fructo-oligosaccharide, xylo-oligosaccharide and galacto-oligosaccharide.
2. The composition with the anti-sugar effect according to claim 1, wherein the raw materials comprise, by weight, 15 parts of apple polyphenol, 35 parts of pagodatree flower bud, 15 parts of tea polysaccharide, 5 parts of roxburgh rose, 5 parts of ginseng and 25 parts of prebiotics.
3. Use of a composition with anti-glycaemic effect according to any of claims 1-2 for the preparation of a medicament for the treatment, delay or alleviation of diabetes.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111041930.8A CN113599422B (en) | 2021-09-07 | 2021-09-07 | Composition with anti-sugar effect and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111041930.8A CN113599422B (en) | 2021-09-07 | 2021-09-07 | Composition with anti-sugar effect and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN113599422A CN113599422A (en) | 2021-11-05 |
| CN113599422B true CN113599422B (en) | 2023-09-15 |
Family
ID=78342724
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111041930.8A Active CN113599422B (en) | 2021-09-07 | 2021-09-07 | Composition with anti-sugar effect and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113599422B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116114867B (en) * | 2022-11-24 | 2023-09-29 | 广东金骏康生物技术有限公司 | Anti-saccharification pagodatree flower bud powder and preparation method and application thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110973432A (en) * | 2019-08-20 | 2020-04-10 | 泰州医药城国科化物生物医药科技有限公司 | Ginseng solid beverage and preparation method thereof |
-
2021
- 2021-09-07 CN CN202111041930.8A patent/CN113599422B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110973432A (en) * | 2019-08-20 | 2020-04-10 | 泰州医药城国科化物生物医药科技有限公司 | Ginseng solid beverage and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN113599422A (en) | 2021-11-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Guo et al. | Hypoglycemic effects of polysaccharides from corn silk (Maydis stigma) and their beneficial roles via regulating the PI3K/Akt signaling pathway in L6 skeletal muscle myotubes | |
| Wachtel-Galor et al. | Ganoderma lucidum (‘Lingzhi’), a Chinese medicinal mushroom: biomarker responses in a controlled human supplementation study | |
| Naowaboot et al. | Antihyperglycemic, antioxidant and antiglycation activities of mulberry leaf extract in streptozotocin-induced chronic diabetic rats | |
| Saura-Calixto | Concept and health-related properties of nonextractable polyphenols: The missing dietary polyphenols | |
| Amagase et al. | Lycium barbarum (goji) juice improves in vivo antioxidant biomarkers in serum of healthy adults | |
| Niwa et al. | Ipomoea batatas and Agarics blazei ameliorate diabetic disorders with therapeutic antioxidant potential in streptozotocin-induced diabetic rats | |
| Bao et al. | Effects of grape seed proanthocyanidin extract on renal injury in type 2 diabetic rats | |
| Nasseri et al. | Benefits of curcumin supplementation on antioxidant status in β-Thalassemia major patients: A double-blind randomized controlled clinical trial | |
| US20070088078A1 (en) | Methods for managing adipocyte fat accumulation | |
| Kim et al. | Epicatechin breaks preformed glycated serum albumin and reverses the retinal accumulation of advanced glycation end products | |
| KR20070100390A (en) | Antioxidant dietary supplement | |
| Fidan et al. | The effects of Yucca schidigera and Quillaja saponaria on DNA damage, protein oxidation, lipid peroxidation, and some biochemical parameters in streptozotocin-induced diabetic rats | |
| JP2021508480A (en) | Compositions for managing hyperglycemia and related conditions | |
| Kumari et al. | Therapeutic Effect of Momordica charantia on Blood Glucose, Lipid Profile and Oxidative Stress in Type 2 Diabetes Mellitus Patients: A Randomised Controlled Trial. | |
| CN113599422B (en) | Composition with anti-sugar effect and application thereof | |
| Li et al. | Amauroderma rugosum Protects PC12 Cells against 6‐OHDA‐Induced Neurotoxicity through Antioxidant and Antiapoptotic Effects | |
| Motto et al. | Antidiabetic and antioxidant potential of total extract and supernatant fraction of the roots of Anogeissus leiocarpus in HFD-fed and Streptozocin-induced diabetic rats | |
| CN109090611A (en) | A kind of AGEs composite inhibiting and its application, preparation method, preparation | |
| Seyydi et al. | Exercise and Urtica Dioica extract ameliorate mitochondrial function and the expression of cardiac muscle Nuclear Respiratory Factor 2 and Peroxisome proliferator-activated receptor Gamma Coactivator 1-alpha in STZ-induced diabetic rats | |
| Takemori et al. | Effects of persimmon fruit polyphenols on postprandial plasma glucose elevation in rats and humans | |
| Uclés et al. | Effects of red raspberry polyphenols and metabolites on the biomarkers of inflammation and insulin resistance in type 2 diabetes: a pilot study | |
| Hsia et al. | Capsaicin, an active ingredient from chilli peppers, attenuates glycative stress and restores sRAGE levels in diabetic rats | |
| Lee et al. | Inhibition of melanogenesis by Aster yomena callus pellet extract in melanoma cells and patients with skin pigmentation | |
| Wong et al. | Antidiabetic effect of Ardisia elliptica extract and its mechanisms of action in STZ-NA-induced diabetic rat model via 1H-NMR-based metabolomics | |
| US10322156B2 (en) | Methods of treatment using purified (decolorized) aloe vera leaf dry juice |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |